Corona Remedies, a company in the Pharmaceuticals industry, reported revenue of ₹441 crore and net profit of ₹60 crore for the September 2026 quarter.
Corona Remedies (NSE: CORONA) closed at ₹2,263.20 on 20 Nov 2026. Its market capitalisation is ₹13,842 crore and it trades at 63.0 times earnings.
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.